Robert G. Perry

960 total citations · 2 hit papers
12 papers, 590 citations indexed

About

Robert G. Perry is a scholar working on Hepatology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Robert G. Perry has authored 12 papers receiving a total of 590 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hepatology, 3 papers in Infectious Diseases and 2 papers in Molecular Biology. Recurrent topics in Robert G. Perry's work include Hepatitis C virus research (3 papers), Liver Disease Diagnosis and Treatment (2 papers) and Phytochemistry and Biological Activities (2 papers). Robert G. Perry is often cited by papers focused on Hepatitis C virus research (3 papers), Liver Disease Diagnosis and Treatment (2 papers) and Phytochemistry and Biological Activities (2 papers). Robert G. Perry collaborates with scholars based in United States, Switzerland and India. Robert G. Perry's co-authors include Jens Præstgaard, Daniel Rooks, Olivier Pétricoul, Ronenn Roubenoff, Didier Laurent, Sam Hariry, Estelle Lach‐Trifilieff, Bret H. Goodpaster, Therese Swan and Ram R. Miller and has published in prestigious journals such as Gastroenterology, Journal of Hepatology and Journal of the American Geriatrics Society.

In The Last Decade

Robert G. Perry

10 papers receiving 581 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity

2021 183 citations Steven B. Heymsfield, Laura A. Coleman et al. JAMA Network Open profile →
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

2021 163 citations Rohit Loomba, Rizwana Mohseni et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert G. Perry United States	8	258	226	147	140	101	12	590
Darren M. Gordon United States	11	115 0.4×	409 1.8×	218 1.5×	110 0.8×	50 0.5×	21	655
Liangming Liu China	16	171 0.7×	252 1.1×	80 0.5×	43 0.3×	93 0.9×	51	674
Sachin Majumdar United States	12	109 0.4×	166 0.7×	226 1.5×	216 1.5×	77 0.8×	36	583
Dalong Zhu China	14	169 0.7×	169 0.7×	175 1.2×	194 1.4×	18 0.2×	26	545
Deying Liu China	13	365 1.4×	230 1.0×	107 0.7×	98 0.7×	26 0.3×	33	852
Birgitte Nellemann Denmark	18	395 1.5×	159 0.7×	189 1.3×	200 1.4×	171 1.7×	34	715
Danielle Lann United States	8	110 0.4×	212 0.9×	121 0.8×	182 1.3×	56 0.6×	10	512
Zhang Jin China	14	185 0.7×	224 1.0×	72 0.5×	134 1.0×	15 0.1×	54	705
Hideo Koike Japan	10	71 0.3×	421 1.9×	54 0.4×	70 0.5×	88 0.9×	26	685
Maelle Morgan United Kingdom	8	135 0.5×	94 0.4×	252 1.7×	115 0.8×	25 0.2×	10	586

Countries citing papers authored by Robert G. Perry

Since Specialization

Citations

This map shows the geographic impact of Robert G. Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert G. Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert G. Perry more than expected).

Fields of papers citing papers by Robert G. Perry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert G. Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert G. Perry. The network helps show where Robert G. Perry may publish in the future.

Co-authorship network of co-authors of Robert G. Perry

This figure shows the co-authorship network connecting the top 25 collaborators of Robert G. Perry. A scholar is included among the top collaborators of Robert G. Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert G. Perry. Robert G. Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Loomba, Rohit, Rizwana Mohseni, Kathryn Jean Lucas, et al.. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 161(5). 1475–1486. 163 indexed citations breakdown →

Heymsfield, Steven B., Laura A. Coleman, Ram R. Miller, et al.. (2021). Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity. JAMA Network Open. 4(1). e2033457–e2033457. 183 indexed citations breakdown →

Loomba, Rohit, Mary E. Rinella, Stephen A. Harrison, et al.. (2020). Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1). Journal of Hepatology. 73. S53–S54. 3 indexed citations

Mogalian, Erik, Diana M. Brainard, Anu Osinusi, et al.. (2018). Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Clinical Pharmacokinetics. 57(11). 1449–1457. 9 indexed citations

Brazier, D J, et al.. (2017). Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. Clinical Drug Investigation. 37(11). 1025–1034. 26 indexed citations

Rooks, Daniel, Jens Præstgaard, Sam Hariry, et al.. (2017). Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof‐of‐Concept Study. Journal of the American Geriatrics Society. 65(9). 1988–1995. 157 indexed citations

Shakeri‐Nejad, Kasra, Vassilios Aslanis, Louise Mooney, et al.. (2015). Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Clinical Therapeutics. 37(11). 2489–2505.e2. 13 indexed citations

Biswal, Shibadas, et al.. (2015). Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 53(10). 855–865. 7 indexed citations

Mogalian, Erik, Anita Mathias, J. McNally, et al.. (2014). P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT. Journal of Hepatology. 60(1). S317–S317. 9 indexed citations

10.

Perry, Robert G., et al.. (2010). Evaluation Of In Situ Chemical Oxidation Of Soils At A Mixed Waste Site And Assessment Of Effects On Ground Water Quality.. ScholarWorks@UMassAmherst (University of Massachusetts Amherst). 13(1). 11. 1 indexed citations

11.

Weber, Kenneth A. & Robert G. Perry. (2006). Groundwater abstraction impacts on spring flow and base flow in the Hillsborough River Basin, Florida, USA. Hydrogeology Journal. 14(7). 1252–1264. 19 indexed citations

12.

Lipkin, J., et al.. (1997). RECYCLING OF EXCESS AND DEMILITARIZED ENERGETIC MATERIALS IN COMMERCIAL EXPLOSIVE APPLICATIONS. International Journal of Energetic Materials and Chemical Propulsion. 4(1-6). 177–188.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact